Pembrolizumab in the treatment of refractory primary mediastinal large B-cell lymphoma: safety and efficacy

Camus, Vincent; Bigenwald, Camille; Ribrag, Vincent; Lazarovici, Julien; Jardin, Fabrice; Sarkozy, Clémentine

doi:10.1080/14737140.2021.1953986

Cited by 4 publications

(5 citation statements)

References 131 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ITs have brought about a new era in solid cancer therapy, attaining unprecedented longlasting responses even in metastatic diseases [1]. In the context of hematologic malignancies, similar results have been observed in lymphomas [2][3][4]. In the context of AML, although analogue studies have been conducted, most of them have failed to advance to the third phase, and no drug has yet been approved for AML.…”

Section: Discussionmentioning

confidence: 74%

“…Anti-cancer immune-based therapeutics (ITs) rely on different approaches that aim to support host immune effectors in clearing neoplastic clones. Although ITs have improved the prognosis of several advanced-stage solid tumors (metastatic melanoma, renal cell carcinoma, head and neck cancers, and non-small lung cancer) [1], the benefits of ITs have been limited in relation to hematological malignancies, and are mostly restricted to classical Hodgkin lymphoma and primary mediastinal B cell lymphoma [2][3][4]. In the context of acute myeloid leukemia (AML), despite the introduction of new drugs and the presence of three updated classifications published in 2022 [5,6], which allow for more effective prognostic stratification, no ITs drugs are currently approved.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Immunotherapy with Monoclonal Antibodies for Acute Myeloid Leukemia: A Work in Progress

Molica,

Perrone,

Andriola

et al. 2023

Cancers

View full text Add to dashboard Cite

In the last few years, molecularly targeted agents and immune-based treatments (ITs) have significantly changed the landscape of anti-cancer therapy. Indeed, ITs have been proven to be very effective when used against metastatic solid tumors, for which outcomes are extremely poor when using standard approaches. Such a scenario has only been partially reproduced in hematologic malignancies. In the context of acute myeloid leukemia (AML), as innovative drugs are eagerly awaited in the relapsed/refractory setting, different ITs have been explored, but the results are still unsatisfactory. In this work, we will discuss the most important clinical studies to date that adopt ITs in AML, providing the basis to understand how this approach, although still in its infancy, may represent a promising therapeutic tool for the future treatment of AML patients.

show abstract

Section: Discussionmentioning

confidence: 74%

Section: Introductionmentioning

confidence: 99%

Immunotherapy with Monoclonal Antibodies for Acute Myeloid Leukemia: A Work in Progress

Molica,

Perrone,

Andriola

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…ITs have opened a new era in solid cancer therapy, attaining unprecedented long-lasting responses even in metastatic diseases [1]. In hematologic malignancies, similar results have been observed in lymphomas [2][3][4]. In AML, although analogue studies have been conducted, most of them have failed to advance to phase 3 studies and currently no drug is approved for AML, yet.…”

Section: Discussionmentioning

confidence: 80%

“…Anti-cancer immune-based therapeutics (ITs) rely on different approaches that have the goal to support host immune effectors to clear neoplastic clones. Although ITs have improved the prognosis of several advanced-stage solid tumors (metastatic melanoma, renal cell carcinoma, head and neck cancers, and non-small lung cancer) [1], benefits of ITs have been more limited in hematological malignancies, mostly restricted to classical Hodgkin lymphoma and primary mediastinal B cell lymphoma [2][3][4]. In acute myeloid leukemia (AML) several considerations need to be taken into account to correctly evaluate ITs: AML patients are severely immuno-compromised and the introduction or the addition of novel therapies may potentially alter the landscape of infectious complications with clinical practice guidelines being frequently updated by the European Conference on Infections in Leukemia (ECIL) [5,6].…”

Section: Introductionmentioning

confidence: 99%

Immunotherapy of Acute Myeloid Leukemia: A Work in Progress

Molica,

Perrone,

Rossi

2023

Preprint

View full text Add to dashboard Cite

In the last years, molecularly targeted agents and immune based treatments (ITs) have deeply changed the landscape of anti-cancer therapy. Indeed, ITs proved to be very effective in metastatic solid tumors, where outcomes were extremely poor with standard approaches. Such a scenario has been only partially reproduced in hematologic malignancies. In acute myeloid leukemia (AML), as innovative drugs are eagerly awaited in relapsed/refractory setting, different ITs have been explored, but the results are still unsatisfactory. In this work, we will discuss the most important clinical studies to date adopting ITs in AML, providing the bases to understand how this approach, although still in its infancy, may represent a promising therapeutic tool for the next future treatment of AML patients.

show abstract

“…[4][5][6][7] Despite continuous efforts to use it to treat lymphomas, immunotherapy has only been effective for classic Hodgkin lymphoma (cHL) [8][9][10][11] and primary mediastinal large B-cell lymphoma (PMLBL). 12,13 Even after treating diffuse large B-cell lymphoma (DLBCL)-the most common non-Hodgkin lymphoma-with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy, the 5-year survival rate is approximately 70%. 14 Therefore, we need to improve the prognosis of DLBCL patients through immunotherapy.…”

Section: Introductionmentioning

confidence: 99%

A unique expression pattern of LAG3 distinct from that of other immune checkpoints in diffuse large B‐cell lymphoma

et al. 2023

View full text Add to dashboard Cite

BackgroundAlthough some patients with diffuse large B‐cell lymphoma (DLBCL) show a response to immunotherapy, there are still many who do not respond. This suggests that various immune checkpoints are complicatedly intertwined in the composition of the tumor microenvironment of DLBCL.Patients and MethodsTo comprehensively understand the expression of various immune checkpoint genes in DLBCL, we performed NanoString assay in 98 patients to investigate 579 genes. In addition, we performed immunohistochemistry for LAG‐3 and PD‐L1 to compare the results with expression in NanoString assay.ResultsAs a result of hierarchical clustering of NanoString assay, 98 DLBCLs were classified into three tumor immune microenvironment clusters. Most immune checkpoint genes showed the highest expression in cluster A and the lowest in cluster C. However, the expression of LAG3 was the highest in cluster C and the lowest in cluster A, showing an expression pattern opposite to that of other immune checkpoint genes. In Cluster A, the expression of genes related to T‐cell activity such as CD8A and GZMB was increased. In Cluster C, the expression of genes related to major histocompatibility complex molecules was the highest. Immunohistochemical stains showed modest agreement with the NanoString results but did not help clustering.ConclusionOur results show that the unique expression pattern of LAG3 in DLBCL contrasts with that of other immune checkpoints. We suggest that the combination of anti‐PD‐1/PD‐L1 and anti‐LAG‐3 blockades in the immunotherapy of DLBCL patients can have a synergistic effect, improving the immunotherapy efficacy and outcome in DLBCL patients.

show abstract

Pembrolizumab in the treatment of refractory primary mediastinal large B-cell lymphoma: safety and efficacy

Cited by 4 publications

References 131 publications

Immunotherapy with Monoclonal Antibodies for Acute Myeloid Leukemia: A Work in Progress

Immunotherapy with Monoclonal Antibodies for Acute Myeloid Leukemia: A Work in Progress

Immunotherapy of Acute Myeloid Leukemia: A Work in Progress

A unique expression pattern of LAG3 distinct from that of other immune checkpoints in diffuse large B‐cell lymphoma

Contact Info

Product

Resources

About